Back to today’s briefing

Story perspectives

New Genomic Tool Transforms HER2 Breast Cancer Treatment

3/13/2025

41 5

Summary

HER2DX Assay Impact

A groundbreaking study in Spain examined the HER2DX genomic assay in 297 patients with stage I-III HER2-positive breast cancer. The findings revealed that nearly half of the patients experienced treatment adjustments, often resulting in less intense therapies. This innovative tool not only boosted physician confidence but also projected significant savings of €98,031, underscoring its promise for personalized cancer care.

Summary

Dr. Hurvitz Advances Treatments

At the 42nd Annual Miami Breast Cancer Conference, Dr. Sara A. Hurvitz unveiled groundbreaking advancements in HER2-targeted therapies for metastatic breast cancer. Highlighting the effectiveness of tucatinib and trastuzumab deruxtecan, she illustrated a transformative shift towards systemic treatments, dramatically enhancing survival rates and responses in patients with brain metastases. Hope is on the horizon!

1 of 2

HER2DX Assay Impact

A groundbreaking study in Spain examined the HER2DX genomic assay in 297 patients with stage I-III HER2-positive breast cancer. The findings revealed that nearly half of the patients experienced treatment adjustments, often resulting in less intense therapies. This innovative tool not only boosted physician confidence but also projected significant savings of €98,031, underscoring its promise for personalized cancer care.

1 / 2